What is Resilience?
Headquartered in Paris, Resilience operates at the intersection of technology and clinical medicine, providing comprehensive digital support solutions for patients navigating complex health journeys. The company specializes in oncology, gastroenterology, and psychiatry, offering a sophisticated platform that facilitates remote symptom tracking, professional medical resource access, and scientifically-validated support programs. By enabling seamless communication between patients and their healthcare teams, Resilience enhances therapeutic monitoring and patient education, effectively addressing the critical need for continuous care in the management of chronic inflammatory bowel diseases, depressive disorders, and cancer. Its market position is defined by its ability to integrate digital care pathways into existing medical infrastructures, thereby improving patient outcomes and operational efficiency for healthcare providers.
How much funding has Resilience raised?
Resilience has raised a total of $70M across 2 funding rounds:
Series A
$45M
Other Financing Round
$25M
Series A (2022): $45M with participation from Picus Capital, Seaya Ventures, EXOR, Cathay Innovation, Fondation Santé Service, Macsf, Singular, Vivalto Ventures, and Ramsay Santé
Other Financing Round (2024): $25M led by Picus Capital and Red River West
Key Investors in Resilience
Seaya Ventures
A leading European and Latin-American venture capital firm that invests in value-driven founders building global technology companies with a sustainable approach.
EXOR
An investment holding company that makes medium to long-term strategic investments across diverse sectors including financial services and technology.
Cathay Innovation
A global venture capital firm that supports multi-stage startups by connecting them to a worldwide ecosystem to foster innovation and sustainability.
What's next for Resilience?
With the infusion of this latest capital, Resilience is well-positioned to accelerate its strategic expansion and deepen its technological capabilities. The company is expected to focus on scaling its digital care pathways across new therapeutic areas while strengthening its integration with major European healthcare institutions. As the digital health market matures, Resilience's focus on evidence-based patient support will likely serve as a cornerstone for its long-term growth, potentially facilitating further international market penetration and the development of next-generation predictive health analytics. The continued support from its diverse investor base provides the necessary operational leverage to navigate the complexities of the healthcare sector while maintaining a commitment to high-impact, patient-centric innovation.
See full Resilience company page
